Central nervous system bleeding in pediatric patients with factor xiii deficiency: A study on 23 new cases

Hematology

Volumn 20, Issue 2, 2015, Pages 112-118

  Naderi, Majid ^a   Alizadeh, Shaban ^b   Kazemi, Ahmad ^c   Tabibian, Shadi ^b   Zaker, Farhad ^c   Bamedi, Taregh ^a   Kashani Khatib, Zahra ^d   Dorgalaleh, Akbar ^b  

^a ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

CNS bleeding; Extracranial hemorrhage; FXIII deficiency; Intracranial hemorrhage

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; BLOOD CLOTTING FACTOR 13; SERPINE1 PROTEIN, HUMAN;

ADOLESCENT; ARTICLE; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BRAIN HEMORRHAGE; CASE CONTROL STUDY; CENTRAL NERVOUS SYSTEM BLEEDING; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DNA EXTRACTION; DNA POLYMORPHISM; ECCHYMOSIS; EPISTAXIS; FEMALE; GENE MUTATION; HEMATOMA; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; QUESTIONNAIRE; RECURRENT DISEASE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SCHOOL CHILD; TOOTH EXTRACTION; WOUND HEALING; BLOOD; CENTRAL NERVOUS SYSTEM; GENETIC POLYMORPHISM; GENETICS; METABOLISM; PATHOLOGY; RISK; VASCULARIZATION;

CARBOXYPEPTIDASE B2; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM; CHILD; FACTOR XIII; FACTOR XIII DEFICIENCY; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; ODDS RATIO; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 84923342098     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845414Y.0000000172     Document Type: Article

References (19)

1. Karimi M, Bereczky Z, Cohan N, Muszbek L editors. Factor XIII deficiency. Seminars in thrombosis and hemostasis. 2009; 35(4):426–38.
2. Naderi M, Dorgalaleh A, Tabibian Sh, Alizadeh Sh, Eshghi P, Solaimani G. Current understanding in diagnosis and management of factor XIII deficiency. Iran J Pediatr Hematol Oncol. 2013;3(4):164–72
3. Naderi M, Imani M, Eshghi P, Dorgalaleh A, Tabibian S, Alizadeh S. Factor XIII deficiency in Sistan and Baluchistan province. Sci J Blood Transfus Organ. 2013;10(3):282–8.
4. Naderi M, Eshghi P, Saneei Moghaddam E, Alizadeh Sh, Dorgalaleh A. Safety of human blood products in rare bleeding disorders in southeast of Iran. Haemophilia 2013;19:e90–2.
5. Hsieh L, Nugent D. Factor XIII deficiency. Haemophilia 2008; 14(6):1190–200.
6. Eshghi P, Cohan N, Naderi M, Karimi M. Factor XIII deficiency: a review of literature. Iran J Blood Cancer 2010;4:85–91.
7. Siboni S, Zanon E, Sottilotta G, Consonni D, Castaman G, Mikovic D, et al. Central nervous system bleeding in patients with rare bleeding disorders. Haemophilia 2012;18(1):34–8.
8. Eshghi P, Mahjour S, Naderi M, Dehbozorgian J, Karimi M. Long-term prophylaxis in patients with factor XIII deficiency complicated by intracranial haemorrhage in Iran. Haemophilia 2010;16(2):383–5.
9. Ågren A, Wiman B, Stiller V, Lindmarker P, Sten-Linder M, Carlsson A, et al. Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesis. J Thromb Haemost. 2006;4(1):201–8.
10. Mehta R, Shapiro A. Plasminogen activator inhibitor type 1 deficiency. Haemophilia 2008;14(6):1255–60.
11. Reiner AP, Schwartz SM, Frank MB, Longstreth W, Hindorff LA, Teramura G, et al. Polymorphisms of coagulation factor XIII subunit A and risk of nonfatal hemorrhagic stroke in young white women. Stroke 2001;32(11):2580–7.
12. Naderi M, Dorgalaleh A, Alizadeh S, Kashani Khatib Z, Tabibian S, Kazemi A, et al. Polymorphism of thrombin-activatable fibrinolysis inhibitor and risk of intracranial haemorrhage in factor XIII deficiency. Haemophilia 2014;20(1):e89–92.
13. Trinh CH, Sh ElSayed W, Eshghi P, Miri-Moghaddam E, Zadeh-Vakili A, Markham AF, et al. Molecular analysis of sixteen unrelated factor XIIIA deficient families from south-east of Iran. Br J Haematol. 2008;140(5):581–4.
14. Tamaddon GH, Kazemi A, Rastegar G, Alla F, Hejazi S. Molecular basis of inherited factor XIII-A deficiency among patients from Sistan-Baluchestan. Zahedan J Res Med Sci. 2010;11(4):19–24.
15. Eshghi P, Abolghasemi H, Sanei-Moghaddam E, Anwar R, Jazebi M, Amid A, et al. Factor XIII deficiency in south-east Iran. Haemophilia 2004;10(5):470–2.
16. Nugent D. Corifact/Fibrogammin(R) P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open-label study. Thromb Res. 2012; 130(Suppl 2):S12–4. Epub 2013/03/06.
17. Naderi M, Zarei T, Haghpanah S, Eshghi P, Miri-Moghaddam E, Karimi M. Intracranial hemorrhage pattern in the patients with factor XIII deficiency. Ann Hematol. 2013:1–5.
18. Endler G, Lalouschek W, Exner M, Mitterbauer G, Haring D, Mannhalter C. The 4G/4G genotype at nucleotide position -675 in the promoter region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than controls. Br J Haematol. 2000;110: 469–71.
19. Roest M, van der Schouw YT, Banga JD, Tempelman MJ, de Groot PG, Sixma JJ, et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation 2000;101:67–70.